

TEAM  
IPF

THOROUGH EVALUATION AND APPROPRIATE MANAGEMENT OF  
IDIOPATHIC PULMONARY FIBROSIS



**Register Now**  
for the Live Virtual  
Meetings!

**Thursday, June 3, 2021**  
**6:00 PM – 7:00 PM CDT**  
or  
**Thursday, June 17, 2021**  
**12:00 PM – 1:00 PM CDT**

Held in collaboration with the **Pulmonary Fibrosis Foundation**



#### Speaker

**Lisa H. Lancaster, MD**

Medical Director, Interstitial Lung Disease Program

Professor of Medicine

Division of Allergy, Pulmonary and Critical Care

Medicine

Vanderbilt University Medical Center

Nashville, TN

#### Agenda

- Introduction: The “Alphabet Soup” of ILDs
- Differential Diagnosis of ILDs
- Managing IPF: Comprehensive, Patient-Centered Care
- Q&A

Visit <https://www.paradigmmc.com/902> for more information and to register

#### Target Audience

This activity has been designed to meet the educational needs of pulmonologists, radiologists, and pathologists. It may also benefit primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other allied healthcare providers who are interested or involved in the care of patients with interstitial lung diseases (ILDs).

#### Learning Objectives

Upon completion of this activity, participants should be able to:

- Differentiate idiopathic pulmonary fibrosis (IPF) from other common ILDs, such as connective tissue disease-associated ILD (CTD-ILD), accurately and efficiently using recommended clinical evaluation, radiologic testing, and pathologic testing as needed
- Apply evidence informing the use of antifibrotic therapy, nonpharmacologic strategies, and management of risk factors and comorbidities in patients with IPF to formulate treatment plans
- Individualize treatment of IPF based on patient characteristics and preferences, using shared decision-making

This activity is provided by **Paradigm Medical Communications, LLC.**



#### Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

#### Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.